Key facts
- This page summarizes Patrick Lin's Form 4 filing for Processa Pharmaceuticals, Inc. (PCSA).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 29 Jan 2025, 16:20.
Patrick Lin - 27 Jan 2025 Form 4 Insider Report for Processa Pharmaceuticals, Inc. (PCSA)
- Issuer symbol
- PCSA
- Report date
- 27 Jan 2025
- Net transaction value
- +$34,691
- Form type
- 4
- Accepted by SEC
- 29 Jan 2025, 16:20:23 UTC
- Previous filing
- 02 Aug 2024
- Next filing
- 18 Feb 2025
- SEC filing
- View on sec.gov
- Reporting owner signature
- /s/ Patrick Lin by Michael B. Kirwan, as Attorney-in-Fact
Source evidence
5 source fields
Reporting owner
1 detail
Key filing fact
Patrick Lin filed Form 4 for Processa Pharmaceuticals, Inc. (PCSA) on 29 Jan 2025.
Change
- Previous filing in this sequence was filed on 02 Aug 2024.
- Current net transaction value: +$34,691.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PCSA
transaction
Common Stock
Purchase
- Transaction value
- $34,691
- Shares
- +43,500
- Change %
- Price
- $0.7975
- Shares after
- 43,500
- Date
- 27 Jan 2025
- Ownership
- Lin Family Trust Feb 4, 2024
PCSA
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 29,059
- Date
- 27 Jan 2025
- Ownership
- Direct
* marks a reported price that did not pass the local price check.